Sowell Financial Services LLC Makes New Investment in SOPHiA GENETICS SA $SOPH

Sowell Financial Services LLC acquired a new position in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 341,889 shares of the company’s stock, valued at approximately $2,865,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SOPH. Maven Securities LTD acquired a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at $866,000. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth about $119,000. AWM Investment Company Inc. acquired a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth about $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth about $567,000. Finally, Royal Bank of Canada lifted its holdings in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. 31.59% of the stock is owned by institutional investors.

Insider Activity at SOPHiA GENETICS

In related news, CEO Ross Muken sold 9,838 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $79,982.94. Following the transaction, the chief executive officer owned 660,391 shares in the company, valued at $5,368,978.83. This represents a 1.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 17,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the sale, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 255,662 shares of company stock valued at $1,970,799 over the last ninety days. 4.88% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a research report on Monday, October 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research lifted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock opened at $7.35 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a market cap of $616.63 million, a P/E ratio of -6.39 and a beta of 0.95. The business’s fifty day moving average is $7.92 and its two-hundred day moving average is $6.29. SOPHiA GENETICS SA has a 52 week low of $3.75 and a 52 week high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The business had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.